Abstract
Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. The key properties of the alpha particles generated by 225Ac are the following: i) limited range in tissue of a few cell diameters; ii) high linear energy transfer leading to dense radiation damage along each alpha track; iii) a 10 day halflife; and iv) four net alpha particles emitted per decay. Targeting 225Ac-drug constructs have potential in the treatment of cancer.
Keywords: Actinium-225, 225Ac, alpha particle-emitter, targeted therapy, monoclonal antibody, radioimmunotherapy, nanomaterials, carbon nanotubes, cancer, 225Ac PRODUCTION, Complexing and Chelating Agent Studies
Current Radiopharmaceuticals
Title: Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Volume: 4 Issue: 4
Author(s): David A. Scheinberg and Michael R. McDevitt
Affiliation:
Keywords: Actinium-225, 225Ac, alpha particle-emitter, targeted therapy, monoclonal antibody, radioimmunotherapy, nanomaterials, carbon nanotubes, cancer, 225Ac PRODUCTION, Complexing and Chelating Agent Studies
Abstract: Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. The key properties of the alpha particles generated by 225Ac are the following: i) limited range in tissue of a few cell diameters; ii) high linear energy transfer leading to dense radiation damage along each alpha track; iii) a 10 day halflife; and iv) four net alpha particles emitted per decay. Targeting 225Ac-drug constructs have potential in the treatment of cancer.
Export Options
About this article
Cite this article as:
A. Scheinberg David and R. McDevitt Michael, Actinium-225 in Targeted Alpha-Particle Therapeutic Applications, Current Radiopharmaceuticals 2011; 4 (4) . https://dx.doi.org/10.2174/1874471011104040306
DOI https://dx.doi.org/10.2174/1874471011104040306 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimers Disease: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Prion Protein Peptides as Vaccines
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Microcystin-induced Cytotoxicity and Apoptosis
Mini-Reviews in Medicinal Chemistry Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Medicinal Value and Potential Therapeutic Mechanisms of Gynostemma pentaphyllum (Thunb.) Makino and Its Derivatives: An Overview
Current Topics in Medicinal Chemistry (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy The Contribution of Buckwheat Genetic Resources to Health and Dietary Diversity
Current Genomics Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research NADPH Oxidase and Neurodegeneration
Current Neuropharmacology Characterizing the Relationship Between the Chemical Structures of Drugs and their Activities on Primary Cultures of Pediatric Solid Tumors
Current Medicinal Chemistry The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy
Current Medicinal Chemistry - Anti-Cancer Agents